GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Cyclically Adjusted PB Ratio

Biomarin Pharmaceutical (WBO:BMRN) Cyclically Adjusted PB Ratio : 3.78 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Biomarin Pharmaceutical's current share price is €75.76. Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €20.03. Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio for today is 3.78.

The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:BMRN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.76   Med: 9.02   Max: 27.64
Current: 3.76

During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PB Ratio was 27.64. The lowest was 3.76. And the median was 9.02.

WBO:BMRN's Cyclically Adjusted PB Ratio is ranked worse than
72.05% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs WBO:BMRN: 3.76

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted book value per share data for the three months ended in Mar. 2024 was €24.597. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €20.03 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.80 6.23 5.32 5.41 4.56

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 4.26 4.24 4.56 4.07

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=75.76/20.03
=3.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=24.597/129.4194*129.4194
=24.597

Current CPI (Mar. 2024) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.316 100.560 9.416
201409 7.939 100.428 10.231
201412 8.311 99.070 10.857
201503 13.982 99.621 18.164
201506 13.043 100.684 16.766
201509 12.670 100.392 16.333
201512 13.645 99.792 17.696
201603 12.676 100.470 16.328
201606 10.452 101.688 13.302
201609 13.730 101.861 17.445
201612 15.189 101.863 19.298
201703 14.940 102.862 18.797
201706 14.197 103.349 17.778
201709 13.451 104.136 16.717
201712 13.497 104.011 16.794
201803 12.887 105.290 15.840
201806 13.913 106.317 16.936
201809 14.042 106.507 17.063
201812 14.635 105.998 17.869
201903 14.516 107.251 17.516
201906 14.604 108.070 17.489
201909 15.543 108.329 18.569
201912 15.626 108.420 18.653
202003 16.221 108.902 19.277
202006 15.866 108.767 18.879
202009 18.964 109.815 22.350
202012 18.571 109.897 21.870
202103 19.139 111.754 22.164
202106 19.204 114.631 21.681
202109 19.754 115.734 22.090
202112 20.527 117.630 22.584
202203 21.564 121.301 23.007
202206 22.979 125.017 23.788
202209 24.831 125.227 25.662
202212 23.331 125.222 24.113
202303 23.196 127.348 23.573
202306 23.463 128.729 23.589
202309 24.362 129.860 24.279
202312 24.075 129.419 24.075
202403 24.597 129.419 24.597

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (WBO:BMRN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biomarin Pharmaceutical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (WBO:BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (WBO:BMRN) Headlines

From GuruFocus